The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All subjects who receive a radial forearm free flaps in the included time period, including subjects with head and neck cancer, traumatic defects, chronic wounds, or any other problems that require a radical forearm free flap for reconstruction.
- Have had a distal, anterograde fasciocutaneous flap
- Age ≥ 18 years
- Ability to understand and the willingness to sign an IRB-approved informed consent document.
- Smokers and tobacco users will be included in this study
Exclusion Criteria:
- Subjects who have had an osteocutaneous or musculocutaneous flap.
- Subjects who have a radial forearm flap with a proximal skin flap or subjects that receive a "reverse" radial forearm flap
- Pregnant women will be excluded due to the lack of clinical studies evaluating INTEGRA template in pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Integra and a Split Thickness Skin Graft (STSG)
A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
|
A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
0.012mm STSG
|
|
Active Comparator: Split Thickness Skin Graft (STSG)
reconstruction as dictated by the protocol.
They will either receive 1) a 0
|
0.012mm STSG
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Skin Graft Necrosis.
Time Frame: 1 year
|
Number of participants with skin graft necrosis.
|
1 year
|
|
Vancouver Scar Scale
Time Frame: 1 Year
|
The Vancouver Scar Scale will measure donor site aesethetic quality and it encompasses 4 separate outcomes to be objectively assessed.
Each has been separately reported in the literature for each group in different papers as previously mentioned.
We will compare the final score as well as scores within each outcome.On a scale of 1-13; with higher score denoting worse outcome.
|
1 Year
|
|
Vancouver Scar Scale - Pigmentation
Time Frame: 1 year
|
Pigmentation will be measured on the Vancouver Scar Scale.
On a scale of 0-2; higher score denoting worse outcome.
|
1 year
|
|
Vancouver Scar Scale - Vascularity
Time Frame: 1 year
|
Vascularity will be measured on the Vancouver Scar Scale.
On a scale of 0-3; higher score denoting worse outcome.
|
1 year
|
|
Vancouver Scar Scale - Pliability
Time Frame: 1 year
|
Pliability will be measured on the Vancouver Scar Scale.
On a scale of 1-5; higher score denoting worse outcome.
|
1 year
|
|
Vancouver Scar Scale - Height
Time Frame: 1 year
|
Height will be measured on the Vancouver Scar Scale.
On a scale of 0-3; higher score denoting worse outcome.
|
1 year
|
|
Hand Strength -Lateral Pinch
Time Frame: Pre-op
|
Functional outcomes will be measured by using strength dynamometers.
|
Pre-op
|
|
Hand Strength -Lateral Pinch
Time Frame: 3 month
|
Functional outcomes will be measured by using strength dynamometers.
|
3 month
|
|
Hand Strength -Lateral Pinch
Time Frame: 6 months
|
Functional outcomes will be measured by using strength dynamometers.
|
6 months
|
|
Hand Strength -Lateral Pinch
Time Frame: 1 year
|
Functional outcomes will be measured by using strength dynamometers.
|
1 year
|
|
Hand Strength - Grip
Time Frame: pre-op
|
Functional outcomes will be measured by using strength dynamometers.
|
pre-op
|
|
Hand Strength - Grip
Time Frame: 3 month
|
Functional outcomes will be measured by using strength dynamometers.
|
3 month
|
|
Hand Strength - Grip
Time Frame: 6 month
|
Functional outcomes will be measured by using strength dynamometers.
|
6 month
|
|
Hand Strength - Grip
Time Frame: 1 year
|
Functional outcomes will be measured by using strength dynamometers.
|
1 year
|
|
Hand Strength- Pincer
Time Frame: pre-op
|
Functional outcomes will be measured by using strength dynamometers
|
pre-op
|
|
Hand Strength- Pincer
Time Frame: 3 month
|
Functional outcomes will be measured by using strength dynamometers
|
3 month
|
|
Hand Strength- Pincer
Time Frame: 6 month
|
Functional outcomes will be measured by using strength dynamometers
|
6 month
|
|
Hand Strength- Pincer
Time Frame: 1 year
|
Functional outcomes will be measured by using strength dynamometers
|
1 year
|
|
Wrist Range of Motion- Flexion
Time Frame: pre-op
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
pre-op
|
|
Wrist Range of Motion- Flexion
Time Frame: 3 month
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
3 month
|
|
Wrist Range of Motion- Flexion
Time Frame: 6 month
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
6 month
|
|
Wrist Range of Motion- Flexion
Time Frame: 1 year
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
1 year
|
|
Wrist Range of Motion- Extension
Time Frame: pre-op
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
pre-op
|
|
Wrist Range of Motion- Extension
Time Frame: 3 month
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
3 month
|
|
Wrist Range of Motion- Extension
Time Frame: 6 month
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
6 month
|
|
Wrist Range of Motion- Extension
Time Frame: 1 year
|
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements.
Wrist flexion and wrist extension
|
1 year
|
|
Number of Participant With Tendon Exposure
Time Frame: 6 month
|
Tendon exposure identified clinically.
|
6 month
|
|
Rate of Tendon Exposure
Time Frame: 1 year
|
Tendon exposure identified clinically.
|
1 year
|
|
Patient Scar Assessment- Paresthesia
Time Frame: 3 month
|
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
|
3 month
|
|
Patient Scar Assessment- Paresthesia
Time Frame: 6 month
|
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
|
6 month
|
|
Patient Scar Assessment- Paresthesia
Time Frame: 1 year
|
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
|
1 year
|
|
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Time Frame: pre-op
|
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale.
On a scale of 0-100; with higher score denotes worse outcome measure
|
pre-op
|
|
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Time Frame: 3 month
|
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale.
On a scale of 0-100; with higher score denotes worse outcome measure
|
3 month
|
|
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Time Frame: 6 month
|
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale.
On a scale of 0-100; with higher score denotes worse outcome measure
|
6 month
|
|
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Time Frame: 1 year
|
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale.
On a scale of 0-100; with higher score denotes worse outcome measure
|
1 year
|
|
Percent of Wound Contracture
Time Frame: 3 month
|
Planimetry Software will be used to measure and determine percentage of wound contracture
|
3 month
|
|
Percent of Wound Contracture
Time Frame: 6 month
|
Planimetry Software will be used to measure and determine percentage of wound contracture
|
6 month
|
|
Percent of Wound Contracture
Time Frame: 1 year
|
Planimetry Software will be used to measure and determine percentage of wound contracture
|
1 year
|
|
Skin Pliability
Time Frame: 1 year
|
Skin pliability will be measuredusing a Cutometer MPA 580.
We plan to measure Pliability (Ua), Elasticity (Ue), Retraction (Ur).
Viscoelasticity (Uv), and Extension (Uf).
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Scar Assessment
Time Frame: 3 month
|
Total score (20-200).
Higher scores denote worse outcomes.
|
3 month
|
|
Patient Scar Assessment
Time Frame: 6 month
|
Total score (20-200).
Higher scores denote worse outcomes.
|
6 month
|
|
Patient Scar Assessment
Time Frame: 1 year
|
Total score (20-200).
Higher scores denote worse outcomes.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Joseph Molnar, MD, PhD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00031531
- CCCWFU 99915A (Other Identifier: Wake Forest University Health Sciences)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.